Shivom Teams Up With SingularityNet to Drive Genomic Medical Research with AI

MUNICH, Germany, June 29, 2018 — Shivom, the decentralized platform creating the world’s largest genomic data hub, is announcing its partnership with SingularityNet, the blockchain-based platform and marketplace for Artificial Intelligence. Shivom and SingularityNet will combine blockchain, AI, and genomic research into a cross-disciplinary, information-theoretic technology to achieve advanced, personalized medical analytics.

Shivom’s decentralized platform will provide an integrated solution for patients and genome data donors, in which genomes can be sequenced and securely stored. This creates an open-web marketplace that service providers, such as pharmaceutical companies, research organizations, governments, patient-support groups and insurance companies, can use. Service providers will be able to add their apps and services alongside genomic data analytics and personalized medicine to the platform. SingularityNET’s bio-AI team is involved with a number of research projects including those that look at the genomics of longevity in an effort to support medical research aimed at maximizing the healthy human lifespan. 

SingularityNET and Shivom established a partnership to connect their networks and maximize  the respective science and engineering teams of each company. Once the integration is complete, AI agents on SingularityNET that require genomic or other biological data to complete tasks will be able to request datasets from Shivom. In return, if a Shivom customer requests that AI analytics are to be performed on the medical data they have uploaded, the Shivom network will be able to request the technology from SingularityNET. SingularityNET and Shivom expect to accelerate these services through their combined networks, providing customers, researchers, and medical professionals with a clear and enhanced understanding of personalized health analytics. 

This cross-network activity will occur with automatic conversion between SingularityNET AGI Tokens and Shivom Tokens, with appropriate encryption within data sharing, as well as the ability for cross-network rating and reputation management. SingularityNET and Shivom expect to create the underpinnings of these services, along with multiple further innovations in AI-driven genomic and medical analytics.

“We are excited to work with SingularityNET. AI approaches are well suited to model the complex dependencies in the regulatory landscape of our genome and can help to predict an individual’s probability of developing certain diseases,” says Co-Founder and CEO of Shivom, Dr. Axel Schumacher. “Such information should be made actionable. As such, we are confident that AI will play a central role in our platform for achieving greater depth in the interpretation of genetic information such as how an individual’s genes may impact their lifestyle decisions or help their healthcare providers to design of potential therapies.” 

“We are enthused to have the opportunity to support Shivom’s vision of next-era genomic research,” says SingularityNET CEO, Dr. Ben Goertzel. “The Shivom vision synergizes beautifully with the SingularityNET vision; the integration of Shivom’s technology, tools, and data with our SingularityNET mind-network will add more scope and intelligence into the field of personalized medical analytics.I. Together, we can achieve great things for medical science by utilizing high-quality datasets, SingularityNET’s algorithms and customer base for biomedical analytics services, and Shivom’s genomics-focused software.”